关于联合加工API的评论,作为改善制药行业可持续性的有希望的方法
Luke Schenck1, Bailey Risteen2, Lindsay Michelle Johnson2
1Oral Formulation Sciences, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
Journal of pharmaceutical sciences
|December 8, 2023
概括
通过共同加工重新考虑活性药物成分 (API) 合成,可以获得显著的可持续性收益. 这种方法减少了辅助剂的使用,加工步骤和包装需求,以实现更绿色的制药制造.
科学领域:
- 制药制造业 制药制造业 制药制造业
- 绿色化学是一种绿色化学.
- 可持续发展 可持续的发展
背景情况:
- 制药生产面临着提高可持续性和减少排放的压力.
- 活性药物成分 (API) 的线性合成和加工存在挑战,特别是具有困难物理化学性质的API.
- 这些挑战包括大量的辅助剂使用,复杂的制造和苛刻的包装要求.
研究的目的:
- 探索在重新思考药品合成和加工中的可持续性机会.
- 引入和定义共同处理的API,作为一种提高可持续性的新方法.
- 详细介绍一系列可持续性影响,包括商业,监管和质量方面的考虑.
主要方法:
- 定义共同加工的API是通过在制药物制造过程中添加非共价键,非活性成分而制造的材料.
- 分析共同加工的API与传统形式 (如盐,溶酸盐和共同晶体) 有何不同.
- 检查共同加工的API在修改药物特性和制造工艺方面的潜力.
主要成果:
- 同时加工的API可以显著减少对辅助剂的需求.
- 它们简化了加工,使其适合连续制造.
- 有机会减少对高度保护性包装的依赖.
结论:
- 共同加工的API代表了范式的转变,模糊了药物物质和药物产品操作,以提高可持续性.
- 这项技术通过减少废物和能源消耗,为环境带来了巨大的好处.
- 建议进一步商业化共同加工的API技术,以实现更广泛的可持续性影响.
关键词:
共同加工的API是使用的.连续的直接压缩连续的直接压缩连续制造 连续制造制造结晶化 结晶化 结晶化生态设计 生态设计终端到终端的制造业绿色化学是一种绿色化学.粒子工程是什么?粒子工程是什么?可持续发展 可持续性 可持续性更多相关视频
09:28Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation
Published on: May 18, 2020
8.5K
05:45Author Spotlight: Process Development for the Spray-Drying of Probiotic Bacteria and Evaluation of the Product Quality
Published on: April 7, 2023
3.4K
相关概念视频
Prodrugs
2.6K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.6K
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
208
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
208
Drug Discovery: Overview
7.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.9K
Drug Biotransformation: Overview
2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K
Bioequivalence: Overview
1.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.1K
Preclinical Development: Overview
4.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.4K
